Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
American Bitcoin Q1 2026 Earnings Call - Satoshis Per Share Surge 20% Amid Cost-to-Mine Collapse and Record Production
American Bitcoin reported its strongest operational quarter since inception, mining 817 BTC in Q1 2026 while expanding its fleet to nearly 90,000 miners and 28.1 exahash per second of capacity. The co...
- American Bitcoin mined 817 BTC in Q1 2026, a record quarter and 33% of all BTC produced since the company’s March 2025 launch.
- The strategic Bitcoin reserve grew by 1,620 BTC to 7,021 BTC at quarter-end, up from 5,401 BTC at year-end 2025.
- Cost-to-mine fell 23% sequentially to $36,200 per BTC, down from $46,900 in Q4 2025, driven by higher production volume and stable fixed costs.
- +7 more takeaways
KORU Medical Systems Q1 2026 Earnings Call - CEO Transition and Record Revenue Growth Drive Strategic Momentum
KORU Medical Systems delivered a record Q1 2026 with $11.8 million in revenue, up 22% year-over-year, anchored by a recurring patient base of approximately 60,000. Domestic core grew 12% while interna...
- KORU reported record Q1 2026 revenue of $11.8 million, up 22% year-over-year, driven by a recurring base of ~60,000 patients and strong execution across domestic and international markets.
- Domestic core revenue grew 12% year-over-year, outpacing the underlying SCIg market, fueled by new patient diagnosis starts and competitive account conversions.
- International core surged 35% year-over-year, led by pre-filled syringe conversions in Europe and significant distributor orders in new markets, signaling early-stage expansion potential.
- +7 more takeaways
Castle Biosciences Q1 2026 Earnings Call - Revenue Guidance Raised as TissueCypher Surges 58% and AdvanceAD-Tx Gains Traction
Castle Biosciences delivered a robust first quarter, posting revenue of $83.7 million and driving a 36% year-over-year increase in core test report volumes. Management raised its full-year 2026 revenu...
- Revenue reached $83.7 million in Q1 2026, driven by a 36% year-over-year increase in core test report volumes.
- Full-year 2026 revenue guidance was raised to $345 million-$355 million, up from the previous range of $340 million-$350 million.
- TissueCypher volumes surged 58% year-over-year to 11,745 tests, with March setting an all-time monthly record.
- +7 more takeaways
Zevra Therapeutics Q1 2026 Earnings Call - MIPLYFFA Revenue Surges 78% as Company Achieves Half of Diagnosed NPC Patient Base
Zevra Therapeutics delivered a strong first quarter, with total net revenue jumping 78% year-over-year to $36.2 million, driven by a 71% increase in MIPLYFFA net sales. The company has successfully re...
- Total net revenue surged 78% year-over-year to $36.2 million in Q1 2026, with MIPLYFFA net sales contributing $24.6 million.
- Zevra has reached approximately 50% of the estimated 300-350 diagnosed NPC patients in the U.S., totaling 170 prescription enrollment forms since launch.
- MIPLYFFA was formally added to updated NPC clinical practice guidelines, reinforcing its status as a preferred disease-modifying therapy and validating combination treatment strategies.
- +7 more takeaways
LifeVantage Q3 FY2026 Earnings Call - Revenue Plunges 25% as Interim CEO Pivots to Shopify and New Leadership
LifeVantage reported a sharp 25.2% decline in third quarter fiscal 2026 revenue, falling to $43.7 million from $58.4 million a year earlier. The drop was driven by weakening sales of the MindBody GLP-...
- Revenue fell 25.2% year-over-year to $43.7 million, missing prior expectations and driven by a steep decline in MindBody GLP-1 System sales.
- Active consultant accounts in the Americas dropped from 32,000 to 30,000, reflecting broader field attrition and challenging retention dynamics.
- Gross profit margin contracted to 79% from 81% due to elevated shipping, warehouse costs, and inventory obsolescence expenses.
- +7 more takeaways
NerdWallet Inc Q1 2026 Earnings Call - Record Profitability Masks Auto Insurance Headwinds and Aggressive Vertical Integration Bets
NerdWallet delivered a quarter of stark contrasts. Revenue grew 6% to $222 million, but the profit story stole the show. Non-GAAP operating income hit a record $34 million, driven by a deliberate sque...
- Total revenue reached $222 million, up 6% year-over-year, with consumer revenue driving the growth at $198 million, up 10% year-over-year.
- Non-GAAP operating income hit a record $34 million, significantly beating the guidance range of $28 million to $32 million and up from $9 million in the prior-year quarter.
- Adjusted EBITDA also set a new Q1 record at $45 million, supported by strong operating leverage and a sharp reduction in other marketing spend.
- +7 more takeaways
Ibotta Q1 2026 Earnings Call - Revenue Declines Slow, LiveLift Momentum Builds, and Two Exclusive Publisher Wins Signal a Shift
Ibotta delivered another quarter of execution beats, with revenue and Adjusted EBITDA landing above the top end of guidance, even as total revenue declined 2% year-over-year. The core story is a gradu...
- Q1 2026 revenue was $82.5 million, a 2% year-over-year decline, but both revenue and Adjusted EBITDA exceeded the top end of guidance, signaling strong execution.
- Redemption revenue declined only 1% year-over-year, a significant improvement from the 15% drop in Q3 2025 and 5% drop in Q4 2025, pointing to a clear bottom in the decline.
- Total redeemers grew 15% year-over-year to 19.7 million, with third-party publisher redemption revenue surging 12% year-over-year to $54 million, demonstrating the success of the IPN expansion.
- +10 more takeaways
Mineralys Therapeutics Q1 2026 Earnings Call - FDA Accepts NDA for Lorundrostat, PDUFA Set for December 2026
Mineralys Therapeutics received FDA acceptance of its New Drug Application for lorundrostat, a novel aldosterone synthase inhibitor targeting uncontrolled or resistant hypertension. The FDA has set a ...
- FDA accepted the NDA for lorundrostat for hypertension in combination with other antihypertensive drugs, with a PDUFA target date of December 22, 2026.
- Lorundrostat's NDA is supported by five pivotal trials: Launch-HTN, Advance-HTN, Transform-HTN, Target-HTN, and Explore-CKD, demonstrating clinically meaningful blood pressure reductions.
- Mineralys ended Q1 2026 with $646.1 million in cash equivalents and investments, sufficient to fund operations into 2028.
- +7 more takeaways
Magnite Q1 2026 Earnings Call - CTV Contribution Exceeds DV+ as AI and Commerce Media Drive Margin Expansion
Magnite delivered a decisive Q1 2026 performance, with CTV contribution ex-TAC surging 30% to capture 51% of total contribution for the first time. The shift away from traditional DV+ is no longer a h...
- CTV contribution ex-TAC grew 30% year-over-year to $82 million, surpassing DV+ to represent 51% of total contribution for the first time.
- Total revenue reached $164 million, up 6% year-over-year, with Adjusted EBITDA of $43 million and a 27% margin, beating consensus by $5 million.
- DV+ contribution ex-TAC declined 5% to $79 million, but management noted stabilization trends in mobile in-app, audio, and commerce media.
- +9 more takeaways
ADMA Biologics Q1 2026 Earnings Call - ASCENIV Demand Remains Robust Amid Standard IG Market Dislocation
ADMA Biologics reported flat top-line revenue in Q1 2026, but adjusted net income surged 22% year-over-year, driven by margin expansion and disciplined cost management. The core narrative centers on a...
- Total revenue came in flat year-over-year at $114.5 million, masking a significant product mix shift between ASCENIV and BIVIGAM.
- ASCENIV revenue grew 28% year-over-year to $97.5 million, supported by record new patient starts, prescriber adoption, and patient adherence.
- BIVIGAM revenue collapsed 54% year-over-year to $15.4 million, disproportionately impacted by aggressive discounting and inventory buildup from new standard IG entrants.
- +7 more takeaways